Videos

"What we found was that we were able to identify patients who responded vs didn't respond to the treatment with a high degree of accuracy," says Glenn T. Werneburg, MD, PhD.

"We're going to look at whether that difference in the protocol has clinically meaningful implications, such as are patients who receive antibiotic prophylaxis at higher risk of developing resistance in the future?" says Badar M. Mian, MD.

"I emphasized the fact that the use of ultrasound is very important and should be done on every single case," says Nazih Paul Khater, MD, FACS.

“But all in all, one thing we did see was that [with] the data for saw palmetto, there was a signal that does seem promising, especially when used in combination with other agents,” says Bilal Chughtai, MD.

"The biggest finding was that the guys lost the weight. They lost 5.5% of their body weight," says Jill M. Hamilton Reeves, PhD, RD, CSO.

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

“We don't have the sex therapists or psychologists who specialize in sexual dysfunction here... It's incredibly important, because if it doesn't start out as psychological, certainly, it becomes psychological, at least in some measure,” says Thomas M. Jaffe, MD.

Experts in prostate cancer evaluate the data from the SPOTLIGHT trial and the use of 18F-rhPSMA-7.3 for prostate cancer.

A panel of experts introduce the SPOTLIGHT study, evaluating PSMA PET in patients with prostate cancer.

"I would say that the biggest take-home is that many of our patients are using social media for their health care information, and this may influence their preferences [and] their decision-making," says Alexandra Tabakin, MD.

"The learning curve is fairly quick; you can pick this up pretty easily vs some of the other prostate procedures that can take a little bit more time to learn how to use," says Matthew E. Sterling, MD.

In this episode, Dr. Kennelly, alongside Dr. Eilber and Dr. Benson, explores the advancements of transcutaneous and posterior tibial nerve stimulation (TTNS and PTNS) and sacral neuromodulation (SNM). The episode sheds light on how these therapies fit into current medical practices, their effectiveness, and the convenience they offer to patients. The specialists consider patient preferences and compliance challenges in choosing the right therapy. The episode provides a comprehensive understanding of how these therapies fit into patient-centric management plans, offering valuable insights for both patients and healthcare professionals.

In this insightful episode, Dr. Kennelly, along with Dr. Eilber and Dr. Benson, discuss the transition from pharmacologic treatments to third-line therapies for overactive bladder, focusing on the mechanism of action of various neuromodulation methods and benefits they offer to patients seeking sustainable solutions for OAB management.

"in general, we can use a simpler regimen [of testosterone replacement therapy] and achieve normal levels," says Peter N. Tsambarlis, MD.

“What we found was that the rate of complications due to infection were 2.6% with the transrectal approach, and 2.7% with the transperineal,” says Badar M. Mian, MD.

"There are situations where you can use a biparametric or noncontrast approach; most of them you will prefer still to use an approach with contrast," says Leonardo Kayat Bittencourt, MD, PhD.

“With 2 years of follow-up, we saw that there was no difference in these 2 groups in terms of overall survival, metastasis-free survival, or recurrence-free survival,” says Saum B. Ghodoussipour, MD.

"You could look at a person and say that they're extraordinarily successful...but they can be completely miserable," says Anne M. Suskind, MD, MS, FACS, FPMRS.

"Probably the most surprising finding was actually that there were several videos created by health care professionals that contain misinformation," says Alexandra Tabakin, MD.

“We’re in a very exciting time for those of us who take care of patients with bladder cancer. There are a lot of new emerging treatment options,” says Vikram M. Narayan, MD.

“In this study, we sought to compare our early outcomes with transperineal prostate biopsy compared to transrectal,” says Saum B. Ghodoussipour, MD.

"We had interest in trying to look at mechanisms and seeing if the obvious question is, well, if obesity is associated with progressing cancer, can we disrupt that link if we help men lose weight in a healthy way," says Jill Hamilton Reeves, PhD, RD, CSO.

"The limitation of [TURP] is you're shaving out prostate tissue in a layer at a time, and you stop when you think you're deep enough, whereas with an Aquablation, you map all that out ahead of time," says Brian Friel, MD.

“It seems that DRE does not add a clinically or statistically significant [benefit] to PSA testing alone in detecting prostate cancer,” says Shahrokh F. Shariat, MD.

Dr. Chapin and fellow expert oncologists discuss the latest data from the LIGHTHOUSE trial, evaluating 18F-rhPSMA-7.3 for staging patients with prostate cancer.

Oncologists share their clinical perspectives of PSMA PET imaging and the results of the patient case.

"We have information today from a number of well-powered, well-designed prospective studies showing that performing an MRI before the decision to do the first biopsy adds value," says Leonardo Kayat Bittencourt, MD, PhD.

“Our hope is to really change the practice of medicine,” says Jim C. Hu, MD, MPH.

"Overall, our conclusion is we observed more benefit in apalutamide vs abiraterone," says Mehmet Asim Bilen, MD.